MXCT.LSE MaxCyte Inc

Healthcare Health Care Equipment & Supplies London Exchange
1.52 GBX
Close of Aug 27, 2025
0.6434 1.81
Market cap
GBX 162M
P/E
-
P/B
1.16x
ROE
-23.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2025.

Is MXCT.LSE undervalued?

Graham number

The Graham number of MaxCyte Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MaxCyte Inc fundamental analysis

No fundamental analysis for MaxCyte Inc yet.

MaxCyte Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MaxCyte Inc

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in thera…

Full company profile